Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06140420 · ClinicalTrials.gov registry record · Phase 4
Naltrexone for Prolonged Grief Disorder
A Phase 4 study, sponsored by Texas Tech University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT06140420: Clinical Trial Phase 4 study, sponsored by Texas Tech University.
NCT06140420 is a Phase 4 study that was terminated before completion, run by Texas Tech University. The registered enrollment target is 7 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06140420, a Phase 4 study, was terminated before completion, sponsored by Texas Tech University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
Primary Outcome
Change in PGD symptom severity will be measured by using Prolonged Grief-13 (PGD-12), a self-rated scale consisting of 12 items. For this study, we have added an additional item inquiring about loneliness to be congruent with DSM-5-TR criteria and SCIP. This 5-point Likert-type of measurement tool evaluates the intensity and severity of the PGD. The validity and reliability of the PGD-12 was tested and validated in previous studies.
Interventions
- DRUG Placebo
- DRUG Naltrexone Oral Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-02-01 |
| Phase | Phase 4 |
Why NCT06140420 stopped before completion
NCT06140420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06140420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06140420 about?
NCT06140420 is a clinical study titled "Naltrexone for Prolonged Grief Disorder". This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
What is the current status of trial NCT06140420?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2023-08-01. Estimated completion is 2025-02-01.
What interventions are being tested in trial NCT06140420?
The interventions under investigation include: Placebo (DRUG), Naltrexone Oral Product (DRUG).
Who is sponsoring clinical trial NCT06140420?
This trial is sponsored by Texas Tech University, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06140420's enrollment target sits among peer trials
7 1981st of 2000 higher than 18 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI